{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T16:26:56Z","timestamp":1787416016670,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejca.2026.116938","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:18:45Z","timestamp":1783628325000},"page":"116938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Assessing time to symptomatic progression, a patient-relevant efficacy endpoint, in the MARIPOSA study in non-small cell lung cancer"],"prefix":"10.1016","volume":"245","author":[{"given":"Danny","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9219-3350","authenticated-orcid":false,"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4739-5631","authenticated-orcid":false,"given":"Chien-Chung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaiyut","family":"Charoentum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Melo","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5856-5512","authenticated-orcid":false,"given":"Hiroaki","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2672-7913","authenticated-orcid":false,"given":"Ruben","family":"Kowalyszyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cagatay","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin D.","family":"Forster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9143-751X","authenticated-orcid":false,"given":"Damien","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Misch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizbett Vanessa Garc\u00eda","family":"Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirish M.","family":"Gadgeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Cruz-Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Schuette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Sermon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronja","family":"Ker\u00dfenboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Frosien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janka","family":"Mei\u00dfner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9715-3755","authenticated-orcid":false,"given":"Priya","family":"Ord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariah","family":"Ennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Fennema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4193-841X","authenticated-orcid":false,"given":"Joshua M.","family":"Bauml","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Daksh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5562-270X","authenticated-orcid":false,"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116938_bib1","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1158\/1078-0432.CCR-16-3065","article-title":"Immuno-oncology trial endpoints: capturing clinically meaningful activity","volume":"23","author":"Anagnostou","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116938_bib2","first-page":"35","article-title":"Cancer symptom response as an oncology clinical trial end point","volume":"3","author":"Bouchard","year":"2018","journal-title":"Expert Rev Qual Life Cancer Care"},{"key":"10.1016\/j.ejca.2026.116938_bib3","unstructured":"Tiurdo\u00a0A. Step by Step Guide to Efficacy Analysis in Solid Tumors Oncology Clinical Trials. PhUSE EU Connect 2018. Frankfurt, Germany, 2018."},{"key":"10.1016\/j.ejca.2026.116938_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40268-024-00478-2","article-title":"The importance of patient reported outcomes in oncology clinical trials and clinical practice to inform regulatory and healthcare decision-making","volume":"24","author":"Bellino","year":"2024","journal-title":"Drugs R D"},{"key":"10.1016\/j.ejca.2026.116938_bib5","unstructured":"Janssen Data on File. 20230928 LUNG Symptomatic Progression PowerPoint, 2023."},{"key":"10.1016\/j.ejca.2026.116938_bib6","unstructured":"Johnson & Johnson Data on File. Time to Symptomatic Progression: A Patient-Relevant Clinical Endpoint in Non-Small Cell Lung Cancer. 2024."},{"key":"10.1016\/j.ejca.2026.116938_bib7","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116938_bib8","article-title":"Overall survival with amivantamab\u2013lazertinib in EGFR-mutated advanced NSCLC","volume":"0","author":"Yang","year":"2025","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2026.116938_bib9","unstructured":"European Medicines Agency. Rybrevant (amivantamab) Summary of Product Characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rybrevant-epar-product-information_en.pdf; 2023 [accessed 19 June 2025]."},{"key":"10.1016\/j.ejca.2026.116938_bib10","unstructured":"Food and Drug Administration. FDA Approves Lazertinib with Amivantamab-Vmjw for Non-Small Lung Cancer, https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lazertinib-amivantamab-vmjw-non-small-lung-cancer; 2024 [accessed 17 March 2025]."},{"key":"10.1016\/j.ejca.2026.116938_bib11","unstructured":"Johnson & Johnson Innovative Medicine. MHRA grants marketing authorisation for LAZCLUZE\u00ae(lazertinib) in combination with RYBREVANT\u00ae(amivantamab) for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, https:\/\/innovativemedicine.jnj.com\/uk\/our-innovation\/focus-areas\/oncology\/mhra-approves-lazcluze-rybrevant-nsclc-egfr-treatment; 2025 [accessed 6 June 2025]."},{"key":"10.1016\/j.ejca.2026.116938_bib12","doi-asserted-by":"crossref","unstructured":"Yang J.C.-H., Kim Y.J., Lee S.-H., Liu B., Ostapenko Y., Lu S., et al. Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC Final Overall Survival from the Phase 3 MARIPOSA Study, In European Lung Cancer Congress, Paris, France, 26\u201329 March, 2025.","DOI":"10.1016\/S1556-0864(25)00199-6"},{"key":"10.1016\/j.ejca.2026.116938_bib13","unstructured":"Centre for Evidence-Based Medicine. Number Needed to Treat (NNT), https:\/\/www.cebm.ox.ac.uk\/resources\/ebm-tools\/number-needed-to-treat-nnt; 2026 [accessed March 2026]."},{"key":"10.1016\/j.ejca.2026.116938_bib14","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1002\/sim.5874","article-title":"Estimating the correlation of bivariate failure times under censoring","volume":"32","author":"Schemper","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2026.116938_bib15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cllc.2025.12.005","article-title":"Patient-relevant outcomes from the phase III MARIPOSA-2 trial: amivantamab-chemotherapy versus chemotherapy in EGFR-mutant advanced non-small-cell lung cancer following disease progression on osimertinib","volume":"27","author":"Tomasini","year":"2026","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejca.2026.116938_bib16","article-title":"Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC","volume":"213","author":"Paz-Ares","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2026.116938_bib17","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.jtho.2024.09.187","article-title":"MA12.07 amivantamab plus lazertinib vs osimertinib in first-line, EGFR-mutant advanced NSCLC: patient-relevant outcomes from MARIPOSA","volume":"19","author":"Nguyen","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2026.116938_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.709877","article-title":"Afatinib in EGFR TKI-na\u00efve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: a pooled analysis of three phase IIIb studies","volume":"11","author":"Passaro","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2026.116938_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/JTO.0b013e31815e8b48","article-title":"Lung cancer symptom scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer","volume":"3","author":"de Marinis","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2026.116938_bib20","unstructured":"McGinley J.S., Savord A., Wirth R.J., Ennis M., Sermon J., Sethi S., et al. Relationships between clinician-confirmed symptomatic progression and change in patient-reported outcomes in NSCLC. (Unpublished Results)."},{"key":"10.1016\/j.ejca.2026.116938_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2023.1217793","article-title":"Perspectives of patients with advanced or metastatic non-small cell lung cancer on symptoms, impacts on daily activities, and thresholds for meaningful change: a qualitative research study","volume":"14","author":"Cardellino","year":"2023","journal-title":"Front Psychol"},{"key":"10.1016\/j.ejca.2026.116938_bib22","unstructured":"European Medicines Agency. Appendix 2 to the Guideline on the Evaluation of Anticancer Medicinal Products in Man: The Use of Patient-Reported Outcome (PRO) Measures in Oncology Studies, https:\/\/www.ema.europa.eu\/en\/documents\/other\/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf; 2016 [accessed 19 June 2025]."},{"key":"10.1016\/j.ejca.2026.116938_bib23","unstructured":"European Medicines Agency. Guideline on the Clinical Evaluation of Anticancer Medicinal Products, https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-evaluation-anticancer-medicinal-products-revision-6_en.pdf; 2023 [accessed 19 June 2025]."},{"key":"10.1016\/j.ejca.2026.116938_bib24","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics Guidance for Industry, https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-endpoints-approval-cancer-drugs-and-biologics; 2018 [accessed 17 March 2025]."},{"key":"10.1016\/j.ejca.2026.116938_bib25","unstructured":"Gemeinsamer Bundesausschuss. Justification to the Resolution of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive (AM-RL): Annex XII \u2013 Benefit Assessment of Medicinal Products with New Active Ingredients According to Section 35a SGB V Apalutamide (Reassessment after the Deadline: Non-metastatic Castration-resistant Prostate Cancer), https:\/\/www.g-ba.de\/downloads\/40-268-5911\/2019-08-01_AM-RL-XII_Apalutamid_D-437_TrG.pdf; 2019 [accessed 6 June 2025]."},{"key":"10.1016\/j.ejca.2026.116938_bib26","unstructured":"Gemeinsamer Bundesausschuss. Justification of the Resolution of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive: Annex XII \u2013 Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a (SGB V) Niraparib\/ abiraterone acetate (prostate cancer, metastatic, castration-resistant, BRCA 1\/2 mutations, chemotherapy not clinically indicated, combination with prednis(ol)one), https:\/\/www.g-ba.de\/downloads\/40-268-10460\/2024-05-02_AM-RL-XII_Niraparib_Abirateronacetat_D-998_TrG.pdf; 2024 [accessed 6 June 2025]."},{"key":"10.1016\/j.ejca.2026.116938_bib27","unstructured":"ClinicalTrials.gov. A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer, https:\/\/clinicaltrials.gov\/study\/NCT00883779; 2009 [accessed 17 March 2025]."},{"key":"10.1016\/j.ejca.2026.116938_bib28","unstructured":"ClinicalTrials.gov. A Study in Non-Small Cell Lung Cancer, https:\/\/clinicaltrials.gov\/study\/NCT01232452; 2010 [accessed 17 March 2025]."},{"key":"10.1016\/j.ejca.2026.116938_bib29","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/1471-2407-11-430","article-title":"INSPIRE: a phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian Patients with Unresectable Stage III non-small cell lung cancer","volume":"11","author":"Wu","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2026.116938_bib30","unstructured":"ClinicalTrials.gov. Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC), https:\/\/clinicaltrials.gov\/study\/NCT00102804; 2014 [accessed 17 March 2025]."},{"key":"10.1016\/j.ejca.2026.116938_bib31","unstructured":"ClinicalTrials.gov. Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer, https:\/\/clinicaltrials.gov\/study\/NCT00095199; 2004 [accessed 17 March 2025]."},{"key":"10.1016\/j.ejca.2026.116938_bib32","unstructured":"ClinicalTrials.gov. Study of Taxane\/Carboplatin +\/- Cetuximab as First-Line Treatment for Patients With Advanced\/Metastatic Non-Small Cell Lung Cancer, https:\/\/clinicaltrials.gov\/study\/NCT00112294; 2005 [accessed 17 March 2025]."},{"key":"10.1016\/j.ejca.2026.116938_bib33","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2017.3438","article-title":"Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: the SELECT-1 randomized clinical trial","volume":"317","author":"J\u00e4nne","year":"2017","journal-title":"Jama"},{"key":"10.1016\/j.ejca.2026.116938_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11523-021-00859-6","article-title":"A phase IIIb open-label, single-arm study of afatinib in EGFR TKI-na\u00efve patients with EGFRm+ NSCLC: final analysis, with a focus on patients enrolled at sites in China","volume":"17","author":"Tu","year":"2022","journal-title":"Target Oncol"},{"key":"10.1016\/j.ejca.2026.116938_bib35","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116938_bib36","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116938_bib37","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1200\/JCO.20.01149","article-title":"Randomized trial of afatinib plus cetuximab versus afatinib alone for first-line treatment of EGFR-mutant non-small-cell lung cancer: final results from SWOG S1403","volume":"38","author":"Goldberg","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T16:21:25Z","timestamp":1787415685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926007197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"alternative-id":["S0959804926007197"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116938","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing time to symptomatic progression, a patient-relevant efficacy endpoint, in the MARIPOSA study in non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116938","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116938"}}